Domestic listing status and price of upadatinib

Upadacitinib (Upadacitinib), as an advanced and selective Janus kinase 1 (JAK1) inhibitor, has officially entered the Chinese market, providing new treatment hope for many patients with immune-mediated inflammatory diseases. This innovative drug effectively regulates intracellular signaling by precisely inhibiting the activity of JAK1, thereby reducing the release of pro-inflammatory cytokines, significantly reducing inflammatory reactions, and helping patients better control disease symptoms.

Currently, upadatinib has been widely used to treat moderately to severely active rheumatoid arthritis (RA) and moderate to severe atopic dermatitis (AD span>), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) and other diseases. Its excellent therapeutic effect has been verified in multiple clinical trials, especially for patients who have not responded well to traditional treatments or other biological agents. Upadatinib has demonstrated significant therapeutic advantages.

Upatinib is provided in the form of oral tablets, which are convenient to take. Patients only need to take it once a day, 15 mg each time. However, the specific dosage needs to be adjusted individually according to the patient's condition and the doctor's advice. This convenient medication method greatly improves patients' treatment compliance and helps to better control disease progression.

The launch of upadatinib in China has undoubtedly brought good news to domestic patients. It not only meets patients' needs for highly effective therapeutic drugs, but also promotes the improvement of domestic treatment of related diseases to a certain extent. Patients no longer need to rely on foreign channels to purchase drugs, which reduces the difficulty and cost of purchasing drugs, making treatment more convenient and economical.

It is worth mentioning that Upatinib is also supported by domestic medical insurance policies. As a drug that has been included in the national medical insurance catalog, the price of upadatinib has dropped significantly, and patients can enjoy preferential medical insurance reimbursement when purchasing it in regular hospitals and pharmacies. This policy has greatly reduced the financial burden on patients, allowing more patients who need long-term treatment to afford upadatinib treatment, allowing for stable and continuous treatment.